Int. J. Pharm. Investigation, 2024; 14(4):1035-1041.
https://www.jpionline.org

Review Article

# A Critical Review on Computational Techniques through *in silico* Assisted Drug Design

**Pawan Kumar Gupta, Yogendra Pal, Prashant Kumar, Shweta Gupta, Shiv Dev Singh, Shashi Bhooshan Tiwari***

Department of Pharmacy, MJP Rohilkhand University, Bareilly, Uttar Pradesh, INDIA.

**ABSTRACT**

Advancements in computational techniques have revolutionized the field of drug design, offering a powerful arsenal of tools collectively known as *in silico* methods. This review provides an overview of the diverse computational techniques employed in the *in silico* assisted drug design process. From molecular docking and molecular dynamics simulations to Quantitative Structure-Activity Relationship (QSAR) models and artificial intelligence-based approaches, these methods play a pivotal role in expediting drug discovery and optimization. The utilization of molecular docking facilitates the prediction of ligand-receptor interactions, aiding in the identification of potential drug candidates. Molecular dynamics simulations contribute by unraveling the dynamic behavior of biomolecular complexes, offering insights into their stability and flexibility. QSAR models, relying on mathematical correlations between molecular descriptors and biological activities, enable the prediction of compound behaviors, guiding the optimization of lead compounds. The integration of machine learning and artificial intelligence further enhances drug design workflows. Deep learning algorithms, such as neural networks, have demonstrated remarkable capabilities in predicting complex biological activities and uncovering hidden patterns within large datasets. High-throughput screening, coupled with in silico methodologies, allows for the rapid exploration of vast chemical spaces, accelerating the identification of promising drug candidates. Despite these advancements, challenges persist, including the accurate representation of biological systems, the validation of computational predictions and the ethical implications of relying solely on *in silico* methods. This review critically evaluates the current state of computational techniques *in silico* assisted drug design, highlighting their strengths, limitations and potential future directions. The integration of computational techniques in drug design has significantly reshaped the landscape of pharmaceutical research. As these methods continue to evolve, bridging the gap between computational predictions and experimental validations, the synergy between *in silico* and *in vitro* approaches holds immense promise for the rapid and effective development of novel therapeutic agents.

**Keywords:** Computer Aided Drug Design, Virtual Screening, Molecular Docking, Molecular Modeling.

**Correspondence:**
**Dr. Shashi Bhooshan Tiwari**
Department of Pharmacy, MJP Rohilkhand University, Bareilly-243006, Uttar Pradesh, INDIA.
Email: s.tiwari@mjpru.ac.in

**Received:** 25-11-2023;
**Revised:** 28-12-2023;
**Accepted:** 01-05-2024.

## INTRODUCTION

Computer Aided Drug Design (CADD) is a multidisciplinary field that integrates computational and experimental methods to discover, design and optimize new therapeutic compounds. This approach significantly accelerates the drug discovery process by reducing the time and cost associated with traditional methods. CADD techniques employ various computational tools and algorithms to analyze biological data, predict molecular interactions and guide the development of new drugs. By interpreting and directing studies, computational techniques speed up the drug creation mechanism.[1-3] Computer-Aided Drug Design (CADD) divided into two categories such as Structure-Based Drug Design (SBDD) and Ligand-Based Drug Design (LBDD). The SBDD technique examines the 3D structural data of macromolecular sites, often proteins or RNA, to pinpoint essential interactions and locations crucial to each biological activity. Such knowledge can be used to produce antibiotic treatment that can compete with the site's necessary interactions, disturbing the pharmacological pathways required for microorganism(s) to survive. The aim of the LBDD approach was to recognize known antibiotic ligand for a target and create a Structure Activity Relationship (SAR) between their physiochemical qualities and antibiotic effect.[4-6] The SAR provided data that could be utilized to increase existing molecules. This chapter will offer basic CADD methods for SBDD along with LBDD not limited to synthesizing on technique and targets often investigated in our research for the development of antibacterial drugs.[7,8]

**DOI:** 10.5530/ijpi.14.4.113

Computer-aided drug design plays a crucial role in streamlining the drug discovery process, offering insights into molecular interactions, predicting drug properties and accelerating the identification of promising drug candidates. The accompanying figures visually represent key stages and techniques in the CADD workflow.[9-12]

## MATERIALS AND METHODS

Here's a general outline of materials and methods commonly employed in CADD for drug discovery across various diseases.

### Computational Resources

High-performance computing clusters or cloud computing platforms for running resource-intensive simulations and calculations.

### Software Tools

**Molecular Docking Software:** Autodock, Glide, GOLD.[13-20]

**Molecular Dynamics Software:** GROMACS, AMBER, NAMD.

**Quantum Mechanics Software:** Gaussian, NWChem.

**Structure-Based Design Tools:** PyMOL, UCSF Chimera.[21]

**Ligand-Based Design Tools:** QSAR, CoMFA, CoMSIA.

**Bioinformatics Tools:** BLAST, Clustal Omega.

**Machine Learning Tools:** Scikit-learn, TensorFlow, PyTorch.

### Databases

Protein Data Bank (PDB) for retrieving 3D structures of biological macromolecules.

Chemical databases for ligand structures and properties.[22-25]

### Molecular Structures

3D structures of target proteins obtained from experimental methods (X-ray crystallography, NMR) or predicted structures. Structure of known ligands or potential drug candidates.

### Biological Data

Biological data related to the target, including binding affinities, activity profiles and known ligands.[26]

### Methods

#### *Homology Modeling*

If experimental structures are not available, homology modeling can be employed to predict the 3D structure of the target protein based on the known structure of a homologous protein.

### Molecular Docking

Docking algorithms are used to predict the binding mode and affinity of ligands to the target protein. This helps identify potential drug candidates.




**Figure 1:** Classification of CADD.[27]




**Figure 2:** Screening Workflow in Computer Aided Drug Design (CADD).[28]

## Molecular Dynamics Simulations

Simulations are performed to study the dynamic behavior and stability of protein-ligand complexes over time. This provides insights into the binding interactions.

## Quantum Mechanics Calculations

Quantum mechanics methods can be applied for accurate calculations of electronic properties and energy levels, especially for detailed studies of reaction mechanisms.

## Structure-Based Design

Structural information is used to guide the design of new compounds with improved binding properties. This may involve modifying existing ligands or designing *de novo* compounds.[28]

## Ligand-Based Design

Quantitative Structure-Activity Relationship (QSAR) models are developed to correlate the chemical structure of ligands with their biological activity. This helps predict the activity of new compounds.

## Machine Learning Approaches

Machine learning algorithms are trained on diverse datasets to predict various aspects of drug discovery, including compound activity, toxicity and ADMET properties.

## Virtual Screening

High-throughput virtual screening is performed to filter large chemical databases and prioritize compounds with the highest likelihood of binding to the target.

## Bioinformatics Analysis

Bioinformatics tools are employed for the analysis of sequence data, identification of potential drug targets and understanding the relationships between genes, proteins and diseases.[29]




**Figure 3:** Stages of CADD Process.[29]

## Validation

Predictions made through computational methods need to be validated experimentally. This involves synthesizing and testing selected compounds *in vitro* and *in vivo.*

In the rapidly evolving field of CADD, researchers often combine multiple methods to obtain more accurate and reliable results. The iterative process of computational prediction, experimental validation and refinement is crucial for the success of drug discovery efforts across various diseases.[30]

## Limitations

Computer-Aided Drug Design (CADD) has made significant strides in drug discovery, but it also has its limitations. Here are some of the key limitations associated with CADD.

## Simplistic Models

CADD often relies on simplified models of biological systems. The actual behavior of molecules in a living organism is incredibly complex and many factors may be oversimplified or not fully considered in computational models.[31]

## Lack of Accurate Force Fields

Force fields used in molecular dynamics simulations may not be accurate enough to capture all interactions accurately. The approximation of intermolecular forces can lead to inaccuracies in predicting binding affinities and other important properties.

## Incomplete Biological Understanding

Our understanding of biological systems is still incomplete and many aspects of protein-ligand interactions are not fully understood. This lack of knowledge can limit the accuracy of predictions made by CADD tools.

## Flexibility and Dynamics

Proteins and other biomolecules are flexible and dynamic, undergoing conformational changes. CADD methods may struggle to accurately predict these dynamic changes, leading to inaccuracies in predicting binding modes.[32]

## Validation Challenges

Validating the predictions made by CADD methods can be challenging. Experimental validation is essential, but it can be expensive and time-consuming. Additionally, predictions made *in silico* may not always translate accurately to real-world biological systems.

## Computational Intensity

Some CADD methods, especially those involving molecular dynamics simulations and quantum mechanics calculations, can be computationally intensive. This limits the speed at which large-scale virtual screenings can be performed.

## Data Quality and Quantity

The accuracy of CADD heavily depends on the quality and quantity of available data.[33] Insufficient or biased data can lead to inaccurate predictions, especially in machine learning-based approaches.

## Specificity and Selectivity

Achieving high specificity and selectivity for a particular target can be challenging. CADD methods may sometimes identify

compounds that bind to the target but lack the desired selectivity or have off-target effects.

### Emerging Resistance and Adaptation

Biological systems, especially pathogens, can adapt and develop resistance to drugs over time. CADD methods may not fully account for the dynamic nature of these systems, leading to challenges in predicting long-term efficacy.

### Ethical and Legal Concerns

The use of CADD raises ethical concerns, especially when predicting potential drug candidates without extensive experimental validation. Issues related to intellectual property, safety and regulatory approval can also be challenging. Despite these limitations, CADD remains a valuable tool in drug discovery, often used in conjunction with experimental methods to accelerate the identification and optimization of potential drug candidates. Ongoing research aims to address these challenges and improve the reliability of computational methods in drug design.[34,35]

## DISCUSSION

CADD expedites the drug discovery process by facilitating virtual screening, lead optimization and the prediction of ligand-receptor interactions. This acceleration is crucial in addressing urgent medical needs and optimizing resources. Computational techniques enable rational drug design by providing insights into the three-dimensional structures of biological macromolecules and predicting how potential drug candidates interact with their targets. This rational approach enhances the likelihood of success in the drug development pipeline. CADD reduces the time and costs associated with experimental screening by allowing researchers to focus on a narrower set of compounds with a higher probability of success. This efficiency is particularly important in the context of large chemical spaces. The use of Quantitative Structure-Activity Relationship (QSAR) models and machine learning allows for the prediction of compound properties, including biological activity, toxicity and Absorption, Distribution, Metabolism, and Excretion (ADME) properties. This predictive capability guides decision-making in the early stages of drug development. Computational tools assist in the identification and validation of drug targets through bioinformatics analyses, helping researchers prioritize targets based on their relevance to specific diseases. Molecular docking and dynamics simulations enhance our understanding of the dynamic nature of ligand-receptor interactions. This knowledge is critical for designing molecules with optimal binding affinity and specificity. CADD techniques can be tailored to address the unique challenges of specific diseases. Whether dealing with infectious diseases, cancer, neurodegenerative disorders, or other conditions, computational methods provide a versatile platform for designing disease-specific interventions. While computational predictions are valuable, the synergy between *in silico* and *in vitro/in vivo* experimental validation is essential. This integrated approach ensures the reliability and applicability of the identified drug candidates. The field of CADD is dynamic, with ongoing innovations in algorithms, software tools and methodologies. Researchers continually refine and expand their computational approaches to overcome challenges and improve the accuracy of predictions. As CADD becomes increasingly integral to drug discovery, ethical considerations regarding the balance between *in silico* predictions and experimental validation, as well as issues related to data privacy and intellectual property, merit careful attention. In essence, computer-aided drug design has transformed the drug discovery landscape, offering a powerful suite of tools that complement and enhance traditional experimental approaches. The continued advancement of computational techniques holds great promise for the development of innovative and targeted therapies to address the complex challenges posed by various diseases.

## CONCLUSION

In this *in silico* assisted drug design process offering a powerful arsenal of tools collectively known as *in silico* methods. From molecular docking and molecular dynamics simulations to Quantitative Structure-Activity Relationship (QSAR) models and artificial intelligence-based approaches, these methods play a pivotal role in expediting drug discovery and optimization. The utilization of molecular docking facilitates the prediction of ligand-receptor interactions, aiding in the identification of potential drug candidates. Predictions made through computational methods need to be validated experimentally. This involves synthesizing and testing selected compounds *in vitro* and *in vivo.* CADD expedites the drug discovery process by facilitating virtual screening, lead optimization and the prediction of ligand-receptor interactions. This acceleration is crucial in addressing urgent medical needs and optimizing resources. Computational techniques enable rational drug design by providing insights into the three-dimensional structures of biological macromolecules and predicting how potential drug candidates interact with their targets.

In conclusion, Computer-Aided Drug Design (CADD) techniques play a pivotal role in modern drug discovery efforts across various diseases. The integration of computational methods has significantly accelerated the identification and optimization of potential therapeutic agents.

## ACKNOWLEDGEMENT

We extend our sincere gratitude to the Dean & HOD Pharmacy, MJPRU, Bareilly whose contributions have enriched the completion of this review paper. Their support, guidance and expertise have been invaluable in navigating the complexities of the subject matter.

Special appreciation goes to the Directorate of Research, MJP Rohilkhand University, Bareilly, UP, India for providing support that facilitated the research and writing of this review. Their commitment to advancing scientific inquiry has been a crucial factor in the success of this endeavor.

We would like to acknowledge the valuable input received from colleagues and peers who generously shared their expertise and insights during work. Their contributions have broadened our perspective and enriched the context of this review. This review paper stands as a collaborative effort and we are grateful to each individual and entity that has played a part, no matter how small, in bringing this work to fruition.

## CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

## ABBREVIATIONS

**CADD:** Computer-Aided Drug Design; **QSAR:** Quantitative Structure-Activity Relationship; **Molecular Docking:** The process of predicting the preferred orientation of one molecule to a second when bound together to form a stable complex. **MD:** Molecular Dynamics; **ADME:** Absorption, Distribution, Metabolism and Excretion; **HTS:** High-Throughput Screening; **3D-QSAR:** Three-Dimensional Quantitative Structure-Activity Relationship; **SAR:** Structure-Activity Relationship; **Ligand:** A molecule that binds to another (usually larger) molecule, often a protein and is involved in a biological process, **Receptor:** A molecule in a cell or on the surface of a cell that binds to a specific substance and causes a specific physiologic effect in the cell. **GPCR:** G-Protein Coupled Receptor; **PDB:** Protein Data Bank; **MM/PBSA:** Molecular Mechanics/Poisson-Boltzmann Surface Area; **FBDD:** Fragment-Based Drug Design; **MDCK:** Madin-Darby Canine Kidney (a commonly used cell line in drug permeability studies); **HBD:** Hydrogen Bond Donor; **HBA:** Hydrogen Bond Acceptor; **FDA:** U.S. Food and Drug Administration **IR:** Infrared; **NMR:** Nuclear Magnetic Resonance; **CoMFA:** Comparative Molecular Field Analysis; **CoMSIA:** Comparative Molecular Similarity Indices Analysis; **CAMD:** Computer-Aided Molecular Design; **ROC:** Receiver Operating Characteristic; **Ensemble Docking:** Using multiple structures of a target in docking calculations to account for receptor flexibility.

## REFERENCES

1. Macalino SJ, Gosu VK, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Arch Pharm Res. 2015;38(9):1686-701. doi: 10.1007/s12272-015-0640-5, PMID 26208641.
2. Sabe VT, Ntombela T, Jhamba LA, Maguire GE, Govender T, Naicker T, *et al.* Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: a review. Eur J Med Chem. 2021;224:113705. doi: 10.1016/j.ejmech.2021.113705, PMID 34303871.
3. Surabhi SB, Singh B. Computer aided drug design: an overview. J Drug Deliv Ther. 2018;8(5):504-9. doi: 10.22270/jddt.v8i5.1894.
4. Kapetanovic IM. Computer-aided drug discovery and development (CADD): *in silico*-chemico-biological approach. Chem Biol Interact. 2008;171(2):165-76. doi: 10.1016/j.cbi.2006.12.006, PMID 17229415.
5. Taft CA, Da Silva VB, Da Silva CH. Current topics in computer-aided drug design. J Pharm Sci. 2008;97(3):1089-98. doi: 10.1002/jps.21293, PMID 18214973.
6. Talele TT, Khedkar SA, Rigby AC. Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr Top Med Chem. 2010;10(1):127-41. doi: 10.2174/156802610790232251, PMID 19929824.
7. Nascimento IJ, de Aquino TM, da Silva-Júnior EF. The new era of drug discovery: the power of computer-aided drug design (CADD). Lett Drug Des Discov. 2022;19(11):951-5. doi: 10.2174/1570180819666220405225817.
8. Bharatam PV. Computer-aided drug design. Drug Discov Dev: From Targets and Molecules to Medicines. 2021:137-210.
9. Veselovsky AV, Ivanov AS. Strategy of computer-aided drug design. Curr Drug Targets Infect Disord. 2003;3(1):33-40. doi: 10.2174/1568005033342145, PMID 12570731.
10. Padole SS, Asnani AJ, Chaple DR, Katre SG. A review of approaches in computer-aided drug design in drug discovery. GSC Biol PharmSci. 2022;19(2):75-83. doi: 10.30574/gscbps.2022.19.2.0161.
11. Imam SS, Gilani SJ. Computer aided drug design: A novel loom to drug discovery. Organic & MedicinalChemistry [international journal]. 2017;1(3):113-8.
12. Usha T, Shanmugarajan D, Goyal AK, Kumar CS, Middha SK. Recent updates on computer-aided drug discovery: time for a paradigm shift. Curr Top Med Chem. 2017;17(30):3296-307. doi: 10.2174/1568026618666180101163651, PMID 29295698.
13. Kore PP, Mutha MM, Antre RV, Oswal RJ, Kshirsagar SS. Computer-aided drug design: an innovative tool for modeling. OJMC. 2012;02(4):139-48. doi: 10.4236/ojmc.2012.24017.
14. Das PS, Saha P. AbdulAPJ A review on computer aided drug design in drug discovery. World J Pharm Pharm Sci. 2017;6(7):279-91.
15. Yu W, MacKerell AD. Computer-aided drug design methods. Antibiotics. Methods Protoc. 2017:85-106.
16. Tang Y, Zhu W, Chen K, Jiang H. New technologies in computer-aided drug design: toward target identification and new chemical entity discovery. Drug Discov Today Technol. 2006;3(3):307-13. doi: 10.1016/j.ddtec.2006.09.004, PMID 24980533.
17. Ejalonibu MA, Ogundare SA, Elrashedy AA, Ejalonibu MA, Lawal MM, Mhlongo NN, *et al.* Drug discovery for Mycobacterium tuberculosis using structure-based computer-aided drug design approach. Int J Mol Sci. 2021;22(24):13259. doi: 10.3390/ijms222413259, PMID 34948055.
18. Xiang M, Cao Y, Fan W, Chen L, Mo Y. Computer-aided drug design: lead discovery and optimization. Comb Chem High Throughput Screen. 2012;15(4):328-37. doi: 10.2174/138620712799361825, PMID 22221065.
19. Thakor R, Ailani R, Surani S, Patel B, Patel D. Computer-aided drug designing. Adv Bioinformatics. 2021:151-82.
20. Medina-Franco JL. Grand challenges of computer-aided drug design: the road ahead. Front Drug Discov. 2021;1:728551. doi: 10.3389/fddsv.2021.728551.
21. Lill MA, Danielson ML. Computer-aided drug design platform using PyMOL. J Comput Aid Mol Des. 2011;25(1):13-9. doi: 10.1007/s10822-010-9395-8, PMID 21053052.
22. Loew GH, Villar HO, Alkorta I. Strategies for indirect computer-aided drug design. Pharm Res. 1993;10(4):475-86. doi: 10.1023/a:1018977414572, PMID 8483829.
23. Drie V, John H. Computer-aided drug design: the next 20 years. J Comput Aid Mol Des. 2007;21(10-11):591-601. doi: 10.1007/s10822-007-9142-y, PMID 17989929.
24. Gurung AB, Ali MA, Lee J, Farah MA, Al-Anazi KM. An updated review of computer-aided drug design and its application to COVID-19. BioMed Res Int. 2021;2021:8853056. doi: 10.1155/2021/8853056, PMID 34258282.
25. Hirono S. An introduction to the computer-aided structure-based drug design--applications of bioinformatics to drug discovery. Rinsho Byori Jpn J Clin Pathol. 2002;50(1):45-51. PMID 11871136.
26. Talevi A. Computer-aided drug design: an overview. In: Computational drug discovery and design; 2018. p. 1-19. doi: 10.1007/978-1-4939-7756-7_1, PMID 29594764.
27. Oyedele AK, Ogunlana AT, Boyenle ID, Adeyemi AO, Rita TO, Adelusi TI, *et al.* Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices. Mol Divers. 2022:1-25.
28. Durrant JD, McCammon JA. Computer-aided drug-discovery techniques that account for receptor flexibility. Curr Opin Pharmacol. 2010;10(6):770-4. doi: 10.1016/j.coph.2010.09.001, PMID 20888294.
29. Prajapat P, Agarwal S, Talesara GL. Significance of computer aided drug design and 3D QSAR in modern drug discovery. J Org Chem. 2017;1(1):1.
30. Frye L, Bhat S, Akinsanya K, Abel R. From computer-aided drug discovery to computer-driven drug discovery. Drug Discov Today Technol. 2021;39:111-7. doi: 10.1016/j.ddtec.2021.08.001, PMID 34906321.
31. Manathunga M, Götz AW, Merz KM. Computer-aided drug design, quantum-mechanical methods for biological problems. Curr Opin Struct Biol. 2022;75:102417. doi: 10.1016/j.sbi.2022.102417, PMID 35779437.

32. Anwar T, Kumar P, Khan AU. Modern tools and techniques in computer-aided drug design. MolDocking computer-. AideddrugDes.2021:1-30.
33. Bajorath J. Deep machine learning for computer-aided drug Design. Front Drug Discov. 2022;2:829043. doi: 10.3389/fddsv.2022.829043.
34. Salman MM, Al-Obaidi Z, Kitchen P, Loreto A, Bill RM, Wade-Martins RW. Advances in applying computer-aided drug design for neurodegenerative diseases. Int J Mol Sci. 2021;22(9):4688. doi: 10.3390/ijms22094688, PMID 33925236.
35. Huang HJ, Yu HW, Chen CY, Hsu CH, Chen HY, Lee KJ, *et al.* Current developments of computer-aided drug design. J Taiwan Inst Chem Eng. 2010;41(6):623-35. doi: 10.1016/j.jtice.2010.03.017.

**Cite this article:** Gupta PK, Pal Y, Kumar P, Gupta S, Singh SD, Tiwari SB. A Critical Review on Computational Techniques through *in silico* Assisted Drug Design. Int. J. Pharm. Investigation. 2024;14(4):1035-41.